2019
DOI: 10.21873/cgp.20159
|View full text |Cite
|
Sign up to set email alerts
|

Proteomic Profile of Sorafenib Resistance in Hepatocellular Carcinoma; GRP78 Expression Is Associated With Inferior Response to Sorafenib

Abstract: Background/Aim: The outcome of patients with advanced hepatocellular carcinoma (HCC) remains poor and therapeutic options, including sorafenib, the first anticancer drug proved to prolong survival in patients with advanced HCC, are limited. However, no clinically useful predictive biomarker for sorafenib has been reported. Materials and Methods: We exploited two-dimensional gel electrophoresis coupled with mass spectrometry to find deregulated proteins by using conditioning of a sorafenibresistant HCC cell lin… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

1
10
0

Year Published

2020
2020
2024
2024

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 15 publications
(11 citation statements)
references
References 29 publications
1
10
0
Order By: Relevance
“…These studies suggest that targeting GRP78 for the treatment of cancer is unlikely to have major deleterious side effects [ 31 , 47 , 48 , 49 ]. An elevated GRP78 level has been linked to the acquired resistance of cancer cells to tamoxifen [ 50 ], 5-fluorouracil (5-FU) [ 51 ], gemcitabine [ 52 ], and targeted therapy agents such as sorafenib [ 53 ] and sunitinib [ 54 ]. Regarding the marked effect of the FO and Se combination on GRP78 reduction shown in this study, this combination might have potential in relieving other GRP78-associated treatment resistances of cancer cells.…”
Section: Discussionmentioning
confidence: 99%
“…These studies suggest that targeting GRP78 for the treatment of cancer is unlikely to have major deleterious side effects [ 31 , 47 , 48 , 49 ]. An elevated GRP78 level has been linked to the acquired resistance of cancer cells to tamoxifen [ 50 ], 5-fluorouracil (5-FU) [ 51 ], gemcitabine [ 52 ], and targeted therapy agents such as sorafenib [ 53 ] and sunitinib [ 54 ]. Regarding the marked effect of the FO and Se combination on GRP78 reduction shown in this study, this combination might have potential in relieving other GRP78-associated treatment resistances of cancer cells.…”
Section: Discussionmentioning
confidence: 99%
“…In HCC tumors from patients treated with sorafenib, 73% showed high GRP78 expression, which was associated with the shortest progression-free survival ( 41 ). Elevated GRP78 is also proposed as a predictive biomarker in HCC patients treated with sorafenib ( 43 ). Moreover, GRP78 is linked with activation of the Wnt/catenin pathway in HCC ( 44 ).…”
Section: Er Stress and Immune Suppression In Hccmentioning
confidence: 99%
“…Of note, there were also no small deletions of the HMGA1 and HMGA2 loci indicating rearrangements of these genes or chromosomal bands 6p21 or 12q14-15, respectively, as described in other biphasic breast tumors [ 19 24 ].…”
Section: Discussionmentioning
confidence: 64%